Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation

BACKGROUND: Dabigatran is a direct thrombin inhibitor approved by the FDA in October 2010 for the treatment of nonvalvular atrial fibrillation. Little is known regarding patient adherence to this therapy. OBJECTIVE: To examine adherence and persistence to dabigatran among adults with atrial fibrilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meijia, Chang, Hsien-Yen, Segal, Jodi B., Alexander, G. Caleb, Singh, Sonal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397607/
https://www.ncbi.nlm.nih.gov/pubmed/26521117
http://dx.doi.org/10.18553/jmcp.2015.21.11.1054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397607/
https://www.ncbi.nlm.nih.gov/pubmed/26521117
http://dx.doi.org/10.18553/jmcp.2015.21.11.1054

Ejemplares similares